ÂÜÀòÂÒÂ×

Apollon is the Chief Executive Officer. Apollon acted as Chief Development Officer at iOmx from 2017 until mid of 2019. He has a long-standing track record in biotherapeutics development and has significantly contributed to the development and launch of many biologics products. Before joining iOmx in 2017, he acted as Global Head Large Molecule Bioanalytical R&D and Pharmaceutical Sciences Site Head at Roche Innovation Center Munich. During his career at Roche, starting in 1997, Apollon held several leadership positions in Biologics R&D within Pharma Research and Early Development and has been a key contributor to the foundation, build-up and the evolution of Roche´s global large molecule research organization and pipeline. Apollon is a biologist by training and earned his PhD in Biochemistry in 1995 from the Julius-Maximilians-University of Würzburg, Germany. After a post-doctorate at the Institute for Experimental Cancer Research in Freiburg, Germany, he started his industrial career at Boehringer Mannheim in 1996 as a Senior Scientist in Biotechnology Research.